Cargando…

A multicenter, longitudinal, interventional, double blind randomized clinical trial in hematopoietic cell transplant recipients residing in remote areas: Lessons learned from the late cytomegalovirus prevention trial

PURPOSE: The logistics of conducting double-blinded phase III clinical trials with participants residing in remote locations are complex. Here we describe the implementation of an interventional trial for the prevention of late cytomegalovirus (CMV) disease in hematopoietic cell transplantation (HCT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimball, Louise E., Stevens-Ayers, Terry, Green, Margaret L., Xie, Hu, Flowers, Mary E.D., Jerome, Keith R., LeBlanc, Renee, Dahlgren, Christi, Nichols, W. Garrett, Chemaly, Roy F., Papanicolaou, G., Boeckh, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292623/ https://www.ncbi.nlm.nih.gov/pubmed/28184381 http://dx.doi.org/10.1016/j.conctc.2016.05.002

Ejemplares similares

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
por: Marty, Francisco M., et al.
Publicado: (2018)

Convergent clonal selection of donor- and recipient-derived CMV-specific T cells in hematopoietic stem cell transplant patients
por: Erickson, Jami R., et al.
Publicado: (2022)

1751. The Impact of Prophylactic Systemic Antibiotics (PSA) on Cytomegalovirus (CMV) Infection: A Post-hoc Analysis of a Randomized Controlled Trial (RCT) in Hematopoietic Cell Transplantation (HCT) Recipients
por: Zamora, Danniel, et al.
Publicado: (2019)

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
por: Waghmare, Alpana, et al.
Publicado: (2020)

2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019)

1734. Cytokine Levels in Bronchoalveolar Lavage Fluid of Rhinovirus-Infected Hematopoietic Cell Transplant Recipients: Associations With Mortality
por: Waghmare, Alpana, et al.
Publicado: (2018)

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
por: Dioverti, Veronica, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Cytomegalovirus –The Quest for an Effective Vaccine in Transplant Recipients Continues
por: Boeckh, Michael, et al.
Publicado: (2015)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution
por: Ogimi, Chikara, et al.
Publicado: (2017)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

The challenge of respiratory virus infections in hematopoietic cell transplant recipients
por: Boeckh, Michael
Publicado: (2008)

923. Respiratory Syncytial and Parainfluenza Virus Infection Increase the Risk of Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Xie, Hu, et al.
Publicado: (2021)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

2712. Respiratory syncytial virus (RSV) pre-fusion F antibody titers in hematopoietic cell transplant recipients with upper versus lower respiratory tract infections
por: Kim, Sara R, et al.
Publicado: (2023)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

2886. Retrospective Case–Control Study of the Performance of the Karius Test, a Plasma Microbial Cell-free DNA Next-generation Sequencing test, to Detect Invasive Mold Infections in Hematopoietic Cell Transplant Recipients with Pneumonia
por: Hill, Joshua A, et al.
Publicado: (2019)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Supplemental Oxygen–Free Days in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus
por: Waghmare, Alpana, et al.
Publicado: (2017)

Utility of the Enzyme-Linked Immunospot Interferon-γ–Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2016)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Stern, Lauren, et al.
Publicado: (2019)

Genetic Variants Associated with Drug Resistance of Cytomegalovirus in Hematopoietic Cell Transplantation Recipients
por: Chae, Seungwan, et al.
Publicado: (2023)

Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
por: Khawaja, Fareed, et al.
Publicado: (2019)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
por: Khawaja, Fareed, et al.
Publicado: (2023)

BK Polyoma Virus Nephropathy in Hematopoietic Cell Transplant Recipients with Renal Dysfunction
por: Lee, Yeon Joo, et al.
Publicado: (2017)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

Detection of Adeno-Associated Virus Viremia in Hematopoietic Cell Transplant Recipients
por: Heugel, Judson, et al.
Publicado: (2011)

750. Respiratory Virus Infections and Airflow Obstruction After Allogeneic Hematopoietic Cell Transplantation
por: Boeckh, Michael, et al.
Publicado: (2018)

Incidence and Outcomes of Cytomegalovirus (CMV) Infection among Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Furuno, Jon P, et al.
Publicado: (2017)

2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2022)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Quantification of Cytomegalovirus Glycoprotein Bn DNA in Hematopoietic Stem Cell Transplant Recipients by Real-time PCR
por: Zhang, Xuan, et al.
Publicado: (2012)

Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy
por: Kim, Tark, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hbj8dsl2radel4vip3ghekttlg